文献速递肿瘤 PET/CT

18F-FDG PET/MRI多参数成像预测乳腺癌HER2零表达、低表达与过表达

18F-FDG PET/MRI multiparameter imaging for predicting HER2-zero,-low and -overexpressing in breast cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-06-01

该回顾性研究纳入111例经病理证实的乳腺癌患者,评估18F-FDG PET/MRI多参数成像预测HER2三分类表达的诊断性能,重点关注HER2低表达亚型。结果显示SyMRI衍生的质子密度对区分HER2低表达与零表达有显著价值,多参数联合模型在识别HER2过表达肿瘤方面优于单参数,bootstrap验证表明模型性能稳定。

要点

  • SyMRI质子密度可区分HER2低表达与零表达,AUC为0.728。
  • SER-PD-SUVmax模型区分HER2零表达与过表达,AUC达0.934。
  • LD-SER-SUVmax模型区分HER2低表达与过表达,AUC为0.849。

核心结论

  • 18F-FDG PET/MRI多参数成像可为评估乳腺癌HER2表达状态提供互补信息,对无创识别HER2过表达肿瘤尤其有帮助,并对HER2低表达特征提供初步价值。

研究设计与样本

  • 回顾性研究纳入111例经病理证实的乳腺癌患者,均于2022年8月至2025年2月期间接受18F-FDG PET/MRI检查。
  • 患者分为HER2零表达组(n=27)、HER2低表达组(n=52)和HER2过表达组(n=32)。
  • 提取形态学、功能、合成MRI(SyMRI)和代谢参数,采用单变量和多变量逻辑回归分析识别独立预测因子,并用ROC分析评估诊断性能。
  • 通过bootstrap重采样(1000次迭代)进行内部验证,并生成校准曲线评估模型性能。

主要发现

  • SyMRI衍生的质子密度(PD)显示显著诊断价值,HER2低表达组PD值高于HER2零表达组(P=0.002;AUC=0.728)。
  • 多参数模型在识别HER2过表达肿瘤方面优于单参数。
  • SER-PD-SUVmax联合模型区分HER2零表达与过表达肿瘤的AUC为0.934。
  • LD-SER-SUVmax模型区分HER2低表达与过表达肿瘤的AUC为0.849。
  • Bootstrap验证显示模型性能稳定,AUC仅轻微下降。

关键数值与推荐

  • HER2低表达组与HER2零表达组比较:PD值差异P=0.002,AUC=0.728。
  • SER-PD-SUVmax模型区分HER2零表达与过表达肿瘤:AUC=0.934。
  • LD-SER-SUVmax模型区分HER2低表达与过表达肿瘤:AUC=0.849。

临床怎么用

  • 18F-FDG PET/MRI多参数成像可作为无创评估乳腺癌HER2表达状态的辅助工具,尤其有助于识别HER2过表达肿瘤。
  • SyMRI衍生的PD参数可用于初步区分HER2低表达与零表达,为后续治疗决策提供参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the diagnostic performance of integrated ¹⁸F-FDG PET/MRI multiparametric imaging for predicting the ternary classification of human epidermal growth factor receptor-2 (HER2) expression in breast cancer, with particular emphasis on identifying the emerging HER2-low subtype. METHODS: This retrospective study included 111 pathologically confirmed breast cancer patients who underwent integrated ¹⁸F-FDG PET/MRI between August 2022 and February 2025. Patients were classified as HER2-zero (n = 27), HER2-low (n = 52), or HER2-overexpressing (HER2-oe, n = 32). Morphological, functional, synthetic MRI (SyMRI), and metabolic parameters were extracted. Univariate and multivariate logistic regression analyses were performed to identify independent predictors of HER2 expression status, and diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis. Internal validation was conducted using bootstrap resampling (1000 iterations), and calibration curves were generated to assess model performance. RESULTS: Proton density (PD) derived from SyMRI showed significant diagnostic value, with higher PD values observed in the HER2-low group compared with the HER2-zero group (P = 0.002; AUC = 0.728). Multiparametric models outperformed single parameters in identifying HER2-oe tumors. The combined "signal enhancement rate-proton density value-maximum standardized uptake value" (SER-PD-SUVmax) model achieved an AUC of 0.934 for differentiating HER2-zero from HER2-oe tumors, while the "largest tumor diameter-signal enhancement rate-maximum standardized uptake value" (LD-SER-SUVmax) model yielded an AUC of 0.849 for distinguishing HER2-low from HER2-oe tumors. Bootstrap validation demonstrated stable model performance with only slight reductions in AUC. CONCLUSION: Integrated ¹⁸F-FDG PET/MRI multiparametric imaging may provide complementary information for assessing HER2 expression status in breast cancer and may be particularly helpful for the noninvasive identification of HER2-overexpressing tumors, while offering preliminary value for HER2-low characterization.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Bian Y, Wang J, Chen J, et al. 18F-FDG PET/MRI multiparameter imaging for predicting HER2-zero,-low and -overexpressing in breast cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42223631. doi:10.1007/s00259-026-07980-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。